Skip to content

The effect of anesthetic on postoperative cognitive dysfunction and relative protein in CSF in elder

The effect of anesthetic on postoperative cognitive dysfunction and relative protein in CSF in elder

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-08000187
Enrollment
Unknown
Registered
2008-11-15
Start date
2008-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer disease

Interventions

S group:Continuous spinal anesthesia only. Collecting CSF 1-1.5ml before and 2 hours after anesthesia respectively.
SI group:After continuous spinal anesthesia is stable, we inject propofol 2mg/kg, then insert LMA and make 1-1.5MAC isoflurane inhaled 2 hours continuously to maintain BIS between 50-60, remaining spo
SP group:After continuous spinal anesthesia is stable, inject propofol 2mg/kg, then insert LMA and infuse propofol 2 hours continuously to maintain BIS between 50-60, remaining spontaneously breathing
SD group:After continuous spinal anesthesia is stable, inject propofol 2mg/kg, then insert LMA and make 1-1.5MAC desflurane inhaled 2 hours continuously to maintain BIS between 50-60, remaining sponta

Sponsors

Beijing Friendship Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients aged from 65-75 years old and schedule to undergo lower limb or hypogastrium operation; ASA I-II; without mental or neurologic disease;educated; no disorder in auditus, vision and language. And all patients accept continuous spinal anesthesia.

Exclusion criteria

Exclusion criteria: Patients will be excluded when (1) They are over 75 yrs or below 65 yrs; (2) They can't accept continuous spinal anesthesia; (3) They have mental or neurologic disease; (4) ASA III or higher; (5) They have contraindication to relative drug; (6) They have anxiety-depression or severe complication after operation; (7)They are taking part in other trial.

Design outcomes

Primary

MeasureTime frame
A beta 40 and A beta 42 in CS;

Secondary

MeasureTime frame
IL-1beta, TNF-alpha, S100 beta, NSE in CS;

Countries

China

Contacts

Public ContactBin Zhang
shuibingzb@hotmail.com+86 0 13901111862

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026